These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37816907)

  • 1. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
    Strouse C; Mott SL; Smith BJ; Magalhaes-Silverman M; Farooq U; Zhan F; Jethava Y; Tricot G
    Bone Marrow Transplant; 2024 Jan; 59(1):128-130. PubMed ID: 37816907
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.
    Cao Y; Shang J; Zhai Y; Wang Q; Yan L; Shi X; Wang J; Yao Y; Zhou H; Sun A; Miao M; Fu C; Jin S
    Leuk Lymphoma; 2024 Jul; 65(7):1016-1019. PubMed ID: 38557299
    [No Abstract]   [Full Text] [Related]  

  • 3. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
    Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
    Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Picot J; Cooper K; Bryant J; Clegg AJ
    Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
    Hjorth M; Hjertner Ø; Knudsen LM; Gulbrandsen N; Holmberg E; Pedersen PT; Andersen NF; Andréasson B; Billström R; Carlson K; Carlsson MS; Flogegård M; Forsberg K; Gimsing P; Karlsson T; Linder O; Nahi H; Othzén A; Swedin A;
    Eur J Haematol; 2012 Jun; 88(6):485-96. PubMed ID: 22404182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
    J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of myeloma in patients not eligible for transplantation.
    Jagannath S
    Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
    Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
    Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose therapy and immunomodulatory drugs in multiple myeloma.
    Barlogie B; Shaughnessy J; Zangari M; Tricot G
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):26-33. PubMed ID: 12520482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
    Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
    Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
    Chim CS
    J Transl Med; 2010 Nov; 8():124. PubMed ID: 21108845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.